GLP-1 Drugs List: Every Approved Medication, Class, and Key Difference in 2026

Most people arrive at this topic wanting one thing: a clear, current list of GLP-1 medications available in 2026. That instinct is reasonable, but the landscape has outgrown the simple list. There are now three distinct pharmacological classes, several molecules sold under more than one brand name, three newly approved generics, and three significant FDA approvals in the past year alone.

As of mid-2026, roughly 29 million U.S. adults (about 11% of the adult population, according to Gallup) were using a GLP-1 medication for weight loss. That scale is exactly why accurate, well-organized information matters.

This article is built as a reference for people who want to understand, not just collect names. It moves from pharmacological class to practical clinical distinctions like brand naming and insurance, then to the 2026 updates, the pipeline, and finally to what medication selection actually means inside a supervised program.

How GLP-1 Medications Are Organized: Three Pharmacological Classes

“GLP-1 drugs” is an umbrella term, not a single class of identical medications. These drugs mimic a naturally occurring hormone, glucagon-like peptide-1, that helps regulate appetite, blood sugar, and the rate at which the stomach empties.

Within that umbrella sit three categories:

1. Pure GLP-1 receptor agonists (the original and most established class)
2. Dual GLP-1/GIP agonists (a single approved molecule)
3. Triple agonists (still investigational in 2026)

Class matters because mechanism shapes the side-effect profile, dosing schedule, delivery format, and the degree of metabolic effect observed in clinical trials. Each class is covered in its own section below.

Class 1: Pure GLP-1 Receptor Agonists

Pure GLP-1 receptor agonists bind exclusively to the GLP-1 receptor. This class includes both older, shorter-acting agents and newer, longer-acting formulations, a distinction that affects dosing frequency and tolerability. Much of the evidence base for GLP-1 therapy, including cardiovascular, kidney, and liver outcome data, was built on this class.

Semaglutide: One Molecule, Multiple Brand Names, and the Insurance Confusion It Creates

Semaglutide is a single active ingredient approved under multiple brand names for different indications, which is a common source of patient confusion. There is an injectable formulation approved for type 2 diabetes (weekly injection, lower maximum dose) and a separate injectable approved for chronic weight management (weekly injection, higher maximum dose). There is also an oral formulation approved for type 2 diabetes (a daily pill taken under a specific fasting and water protocol).

In late December 2025, the FDA approved the first oral semaglutide for chronic weight management, which launched January 5, 2026, at a starting cash-pay price of roughly $149 per month. Within three weeks it reached about 170,000 prescriptions, and the oral weight-management formulation topped roughly 3 million prescriptions within five months, the fastest GLP-1 adoption on record. On March 19, 2026, the FDA approved a higher-dose injectable semaglutide; the STEP UP trial showed greater weight reduction than the standard dose.

The insurance logic is key: the label indication (diabetes versus weight management), not the molecule, determines which benefit covers the prescription. An insurer may cover one labeled version and not another.

Liraglutide: The First-Generation Weight-Management GLP-1 and Its New Generic Access

Liraglutide is a daily injectable and one of the earliest agents in the class, with a well-established long-term safety record. It carries two labeled indications: type 2 diabetes (lower dose) and chronic weight management (higher dose).

Access expanded meaningfully here. The first-ever generic GLP-1 in the U.S. was a liraglutide generic (Hikma, December 2024). A second generic referencing the weight-management indication followed (Teva, August 2025), the first generic GLP-1 approved specifically for chronic weight management. Generics expand access for cost-sensitive patients, though the daily injection schedule (versus weekly semaglutide) affects adherence for some.

Dulaglutide: Weekly Injectable for Type 2 Diabetes

Dulaglutide is a weekly injectable approved for type 2 diabetes, with established cardiovascular outcome data supporting GLP-1s as cardiometabolic drugs. It is not approved for weight management as a primary indication. It remains a familiar, well-tolerated option for patients already stable on it, though newer agents have largely superseded it for new prescriptions.

Exenatide: Shorter-Acting Agent and the Second Approved Generic

Exenatide was the earliest GLP-1 receptor agonist to reach the U.S. market, available in twice-daily and extended-release weekly formulations. AstraZeneca discontinued both branded products in October 2024. A generic exenatide (Amneal) was approved in November 2024, keeping the molecule available. Its shorter half-life affects dosing frequency, and it is less potent for weight loss than newer agents, but it carries a long safety record.

Lixisenatide: Discontinued but Historically Relevant

Lixisenatide was a short-acting, once-daily injectable approved for type 2 diabetes. It has since been discontinued in the U.S. market. It is included here for completeness, as readers researching the full class may encounter the name.

Class 2: The Dual GLP-1/GIP Agonist — Tirzepatide

Tirzepatide is the only approved dual agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, adding a complementary metabolic signal that pure GLP-1 agonists do not provide. It carries two labeled indications: type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), following the same insurance logic as semaglutide. The chronic weight management formulation is also approved for obstructive sleep apnea, one of the first GLP-1-class drugs cleared for a non-metabolic comorbidity. In late 2025, the type 2 diabetes indication was expanded to include children as young as 10.

Head-to-head evidence is notable. In the SURMOUNT-5 trial and a 2026 meta-analysis spanning more than 40,000 participants, tirzepatide was consistently associated with greater weight reduction than semaglutide, which is one reason clinicians consider the mechanism differences between agents. It is a weekly subcutaneous injection.

The Two-Brand-Names, One-Molecule Rule: Why It Matters for Coverage

When the FDA approves a drug for a new indication, the manufacturer often files a separate brand name. This is a regulatory and commercial convention, not a pharmacological difference. The consequence is practical: commercial insurers, Medicare, and Medicaid use the labeled indication to set the benefit category. A patient whose plan covers diabetes drugs but not weight-management drugs may find one brand covered and the other denied, even though the molecule is identical. Starting July 1, 2026, the Medicare GLP-1 Bridge program gave millions of eligible seniors access to GLP-1 drugs for weight loss at roughly $50 per month. Understanding this before speaking with a prescriber or insurer can prevent confusion.

Class 3: Triple Agonists — The Investigational Frontier

Triple agonists activate GLP-1, GIP, and glucagon receptors simultaneously. The glucagon signal adds a thermogenic, energy-expenditure effect on top of appetite and insulin regulation. Retatrutide (Eli Lilly) is the most advanced investigational triple agonist; it is in Phase 3 trials, with TRIUMPH-1 data announced in May 2026 and results still under review. No triple agonist is FDA-approved as of September 2026. Separately, CagriSema (a GLP-1/amylin combination) had an NDA filed in December 2025, with an FDA decision expected around October 2026.

The 2026 Approvals: What Actually Changed This Year

2026 was the most active year for GLP-1 regulatory action since the class began, spanning a new delivery format, a new dosing tier, and an entirely new molecular category.

Oral Semaglutide for Weight Management (December 2025 / January 2026 Launch)

The first oral GLP-1 pill for obesity was FDA-approved in late December 2025 and launched January 5, 2026. It requires specific food and water restrictions around dosing. Adoption reached about 170,000 prescriptions in three weeks, with a starting cash-pay price near $149 per month. Because needle aversion is a documented barrier to starting therapy, an oral option removes that barrier for many patients.

High-Dose Injectable Semaglutide (March 2026)

Approved March 19, 2026, this higher-dose injectable extends the existing weight-management option for patients who plateau at the standard maximum dose. The STEP UP trial showed greater weight reduction with the higher dose. This is a new dose of an existing molecule, not a new drug, which affects prescribing and coverage.

Orforglipron (Foundayo): The First Small-Molecule Oral GLP-1 (April 2026)

Approved April 1, 2026, orforglipron (Foundayo, Eli Lilly) is the first non-peptide, small-molecule oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related conditions. Because small molecules are not large proteins, Foundayo can be taken as a standard pill with no food or water restrictions, unlike oral semaglutide. It represents an entirely new molecular category, not a reformulation.

The Three New Generics: What They Mean for Cost and Access

Generics are a structural access story, not a quality story. Three are now approved: Amneal generic exenatide (November 2024), Hikma generic liraglutide for type 2 diabetes (December 2024, the first-ever generic GLP-1 in the U.S.), and Teva generic liraglutide 3mg referencing the weight-management indication (August 2025, the first generic GLP-1 for chronic weight management).

Generics introduce price competition into a market where two manufacturers control roughly 87% of prescription weight-management drug revenue. They reference older molecules with longer safety records that are less potent for weight loss than newer agents, so the tradeoff is cost versus effect, a clinical decision. Medicaid GLP-1 prescriptions grew dramatically from 2019 to 2024, and generics are likely to accelerate that trend.

Expanded Indications: GLP-1 Medications Beyond Diabetes and Weight Loss

GLP-1 medications are increasingly understood as systemic cardiometabolic drugs. Approved expanded indications now include cardiovascular risk reduction (supported by the SELECT trial), obstructive sleep apnea (tirzepatide), chronic kidney disease (a semaglutide diabetes formulation, January 2025), and metabolic dysfunction-associated steatohepatitis, or MASH (a semaglutide weight-management formulation, August 2025). Research published in Nature Medicine and Cell Reports Medicine indicates some of these benefits appear at least partly independent of weight loss, suggesting the mechanism itself contributes to organ-level outcomes. The WHO added GLP-1 therapies to its Essential Medicines List for high-risk type 2 diabetes groups in September 2025. Because the applicable indication depends on a patient’s full clinical picture, a clinician, not self-selection, is the appropriate decision-maker.

Complete Reference Table: All FDA-Approved GLP-1-Class Medications (2026)

Note: Semaglutide formulations are described by indication and delivery format. Investigational agents (retatrutide, CagriSema) are covered in the pipeline section.

What the Clinical Evidence Actually Shows: Comparing Across Classes

Head-to-head trial data, not marketing, is the right basis for comparison. SURMOUNT-5, published in the New England Journal of Medicine, was the first randomized head-to-head trial comparing tirzepatide and a semaglutide weight-management formulation in adults without diabetes; tirzepatide showed greater mean weight reduction at 72 weeks. A 2026 meta-analysis of 10 studies and more than 41,000 participants confirmed that pattern across multiple study designs. Older agents like liraglutide and exenatide are generally less potent for weight loss but carry longer safety records and are now available as generics. Importantly, real-world outcomes often fall short of trial results due to suboptimal titration, poor adherence, and lack of structured support. The most appropriate drug for a given patient depends on comorbidities, insurance, tolerability, and goals, not a ranking list.

Delivery Format and Tolerability: Practical Differences That Affect Daily Life

Delivery formats now range across weekly injectable, daily injectable, daily oral pill with dosing restrictions, and daily oral pill without restrictions (orforglipron). Format affects adherence, and adherence affects outcomes. Oral semaglutide requires fasting and limited water before dosing; Foundayo requires neither. The most common side effects across the class are nausea, vomiting, and other gastrointestinal symptoms, with slow dose titration as the primary mitigation strategy. Needle aversion remains a real barrier, which oral options address. Managing tolerability is a core reason supervised care matters: a clinician can adjust titration, manage side effects, and determine when a different agent is a better fit. 5 yoga poses to aid digestion can also be a helpful complement for patients managing gastrointestinal side effects during titration.

The Compounded GLP-1 Landscape: What Patients Need to Know in 2026

The Investigational Pipeline: What Is Coming After 2026

For readers tracking where the field is heading, the pipeline is active. Retatrutide (Eli Lilly’s triple agonist) is the most advanced investigational agent, currently in Phase 3 trials, with TRIUMPH-1 data announced in May 2026 and results still under review; it is not yet FDA-approved. CagriSema (a GLP-1/amylin combination) had its NDA filed in December 2025, with an FDA decision expected around October 2026, and trial data showed substantial weight reduction. Other agents in development include survodutide, MariTide, and amycretin. The oral GLP-1 segment, including small-molecule agents like orforglipron, is the fastest-growing part of the field. This pace underscores the value of ongoing clinical oversight rather than a single, one-time treatment decision.

Why Medication Choice Is Only One Variable in a GLP-1 Program

The WHO’s December 2025 global guideline conditionally recommends GLP-1 therapies as part of a comprehensive care model that includes a healthy diet, physical activity, and ongoing clinical support, and it explicitly states that medication alone is not a solution. Two clinical realities reinforce this. First, research indicates a meaningful portion of weight lost during GLP-1 treatment can come from lean muscle rather than fat; a six-month study of 200 adults found that supervised care, resistance training, and adequate protein intake were key to preserving muscle. Second, weight regain after stopping GLP-1 therapy is a well-documented concern, reinforcing that medication is a tool within a longer program, not a standalone fix. Because real-world outcomes often trail trial results, supervised programs are the variable that closes the gap. Medication selection is a clinical decision built on a patient’s full metabolic picture, comorbidities, insurance, tolerability, and goals, not a consumer product choice.

What Supervised Care Actually Looks Like — and Why It Changes Outcomes

The elements the WHO guideline and clinical evidence support include structured nutrition strategy, resistance training guidance, metabolic monitoring, dose titration support, and side-effect management. These are not add-ons; they are what determines whether a patient preserves muscle, maintains nutrient balance, sustains results, and avoids the regain pattern seen after unsupervised discontinuation. That is the difference between a medication and a program.

Red Mountain approaches GLP-1 therapy from this vantage point. With more than 30 years of real-world patient outcomes, brick-and-mortar clinics staffed by in-person providers, and programs designed specifically to support patients on GLP-1 medications, the practice focuses on minimizing side effects, preserving muscle mass, and maintaining nutrient balance. Its legacy RM3® program reflects decades of refined clinical experience. Throughout, medication is treated as a tool in service of a larger metabolic correction, not the whole answer. Understanding why GLP-1 medications could be the missing piece in your wellness journey can help patients frame their expectations before beginning a supervised program.

Conclusion: The List Is a Starting Point, Not a Decision

The organizing logic is clear: three pharmacological classes, the dual-brand-name pattern and its insurance implications, three significant 2026 approvals, three new generics, expanded indications beyond diabetes and weight loss, and a fast-moving pipeline. The list itself is a reference, not a prescription. The right medication for a given patient depends on their full clinical picture and, critically, the structure of the program built around it. As the WHO framing makes clear, medication is one component of comprehensive care, not the model itself. The landscape will keep evolving, with new approvals, generics, and combination agents expected over the next 12 to 24 months, which makes ongoing clinical guidance more valuable, not less.

Ready to Understand Which Option Fits Your Clinical Picture?

Anyone who has read this far has done the research and likely wants a clinician who will explain things clearly rather than sell a product. That is the kind of conversation Red Mountain has in every consult: what the options are, what the evidence shows, and what a supervised program looks like for a specific situation. Backed by more than 30 years of clinical experience and an in-person care model, the practice treats the consult as a chance to get answers, not a pressure point. If this sounds like the right next step, a consult is typically where that conversation begins.